Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.

This study observed that women with early-stage breast cancer often felt inadequately prepared for the discomfort and time commitments of scalp cooling during chemotherapy, leading to the development of patient-co-produced informational resources to better prepare them.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.

This article reports a unique case of a 60-year-old woman with alopecia areata and myasthenia gravis, suggesting a rare paraneoplastic syndrome connection primarily limited to prior reports involving hematologic cancers.

This study proposes a new mathematical model, the Harmonic Mean equation, for precisely quantifying nuclear pleomorphism in breast cancer grading, showing high performance with accuracy, recall, specificity, precision, and F1-score metrics.

This policy paper explores the potential of using nanoscale carriers to deliver chemotherapy drugs directly to breast cancer tumors in the UAE, aiming to minimize harmful side effects and improve quality of life for patients by targeting only cancerous cells.

This study found that scalp cooling did not entirely prevent permanent chemotherapy-induced alopecia in breast cancer patients, with a significant risk observed among postmenopausal women undergoing anthracycline and taxane-based chemotherapy.

This study found that patients with ovarian metastases from breast cancer had a better prognosis after tumor debulking if they exhibited high estrogen and progesterone receptor expression in both the primary tumor and metastases.

This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

This study found that scalp hypothermia effectively prevented chemotherapy-induced alopecia in 57.3% of breast cancer patients, with side effects such as a feeling of cold and slight headaches reported in 16% of cases.

In this study, Asian breast cancer patients undergoing taxane-based chemotherapy in the adjuvant treatment group reported significantly increased hair loss, higher melanin index, and more wrinkles compared to other treatments, while most neoadjuvant group patients saw hair loss reversed six months post-surgery.

In this study, combining hair transplantation with platelet-rich plasma was found to be more effective than hair transplantation alone in reducing hair loss, improving hair regeneration, and decreasing skin lesions in patients with androgenic alopecia.

This study found that alpha mangostin protected wild-type MCF10A breast cancer cells, but not p53 knockout cells, from damage by the chemotherapy agent paclitaxel.

In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.

This study assessed Palestinian women newly diagnosed with breast cancer and found that higher spiritual well-being is associated with improved body image and sexual functioning, and reduced distress from treatment side effects, suggesting spiritual support should be integrated into cancer care.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.

In this case report, an 80-year-old woman experienced elevated alkaline phosphatase levels due to the use of Viviscal hair supplements. Her levels returned to normal after discontinuing the supplement, highlighting the need for clinicians to consider supplements as potential causes of abnormal lab results.

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.

This study investigated the effects of Christia vespertilionis extract on breast cancer cell lines, finding that it had a concentration-dependent cytotoxic effect, although less potent than tamoxifen, suggesting potential as an alternative cancer treatment.

In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.

This study found that certain nutraceuticals did not interfere with tamoxifen's inhibition of estrogen in breast cancer cells and may enhance its effects, suggesting potential as an adjuvant therapy for hair loss in patients undergoing endocrine therapy.

This preclinical study found that exercise-induced extracellular vesicles delayed breast cancer tumor growth in mice, potentially by enhancing the immune response within the tumor microenvironment.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

This source discusses the complexity of cancer research, emphasizing that despite extensive studies, a comprehensive understanding of metastatic progression and therapeutic development remains elusive, and underscores the importance of animal models in breast cancer research.

This study found that scalp cryotherapy significantly protected against hair loss during chemotherapy and for two months after, with various factors influencing hair regrowth in breast cancer patients.

This study reported that postmenopausal patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival over therapy-related side effects when considering cancer treatment decisions.